Perfint to commercialise machine to treat cancer
Thanks to fresh funding of USD 11 million, the city-based Perfint Healthcare, a medical equipment firm, would commercialise its latest machine used to treat cancer, develop ultrasound guided procedure and tissue characterisation, besides foraying into the US, Chinese and Japanese markets.
Talking to reporters here today, Perfint CEO S Nandakumar said the funding was received from Norwest Venture Partners.
"We have received 11 million USD from Norwest Venture Partners last week. It will be used for commercialising our new product 'Maxio' and develop ultrasound guided procedure and tissue characterization, get regulatory approvals in US, China and Japan and also expand advanced technology lab in the US," he said.
He said the company would also expand its research and development activity in the US.
The company's latest equipment Maxio helps in non-invasive treatment of cancer. It is an integrated visualization, planning and robotic targeting system for CT (computed tomography) guided tumor ablations (removal of tissue).
He said the company was eyeing a sale of around 200 units of Robio and Maxio by the end of this fiscal to achieve a turnover of ten million USD to achieve the target of 50 million USD turnover by 2016.